Bryostatin 1
Adult Acute Myeloid Leukemia With t(15;17)(q22;q12)
National Cancer Institute (NCI)Small moleculePhase 1Dormant
CC
47/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 32/ 100
- Competitive Position
- 95/ 100
Competitive context
20 Active assets in the Adult Acute Myeloid Leukemia With t(15;17)(q22;q12) cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Cytosin-Arabinosid Associazione Italiana Ematologia Oncologia Pediatrica | Phase 4 | A |
Vesanoid The Affiliated People's Hospital of Ningbo University | Phase 4 | A |
Idarubicine Technische Universität Dresden | Phase 4 | A |
Arsenic Trioxide Quetzal Therapeutics | Phase 4 | BBB |
Mitoxantrone Technische Universität Dresden | Phase 4 | BBB |
View all 50 →
Same molecule, other indications
Bryostatin 1 is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →